The Missouri Department of Health has barred dietary supplement distributor Syntrax Innovations from selling its on-hand supply of a weight loss nutritional supplement due to FDA concerns the product is an unapproved new drug.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.
EU marketing applications for drugs aimed at slowing myopia progression in children and for treating cutaneous T-cell lymphoma have been turned down by the European Medicines Agency.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
